U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H26F3N5O3
Molecular Weight 549.5447
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of UBROGEPANT

SMILES

C[C@]1([H])[C@@]([H])(C[C@@]([H])(C(=O)N1CC(F)(F)F)N=C(c2cc3C[C@]4(Cc3nc2)c5cccnc5N=C4O)O)c6ccccc6

InChI

InChIKey=DDOOFTLHJSMHLN-ZQHRPCGSSA-N
InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1

HIDE SMILES / InChI

Molecular Formula C29H26F3N5O3
Molecular Weight 549.5447
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Ubrogepant, a small molecule drug, is being developed by Merck & Co for the treatment of migraine. The calcitonin gene-related peptide receptor (CGRP) antagonist is administered orally as a film coated tablet. Ubrogepant is a competitive antagonist with high affinity, potency, and selectivity for the human CGRP receptor. In the four clinical studies (ACHIEVE I, ACHIEVE II, UBR-MD-04 and 3110-105-002) ubrogepant demonstrated efficacy, safety and tolerability in the acute treatment of migraine among a broad patient population, including those who had an insufficient response to a triptan or those patients in whom triptans were contraindicated, as well as in patients who had moderate to severe CV risk profile.

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
281.97 nM
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
UBROGEPANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status:
274.25 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
UBROGEPANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1029.75 ng/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
UBROGEPANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1306.54 nM × h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
UBROGEPANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status:
1249.39 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
UBROGEPANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5127.06 ng × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
UBROGEPANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.54 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
UBROGEPANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status:
4.41 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
UBROGEPANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.06 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
UBROGEPANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
25 mg multiple, oral
Dose: 25 mg
Route: oral
Route: multiple
Dose: 25 mg
Sources:
unhealthy, 18-71 years
n = 478
Health Status: unhealthy
Condition: migraine
Age Group: 18-71 years
Sex: M+F
Population Size: 478
Sources:
Other AEs: Upper respiratory tract infection, Nausea...
Other AEs:
Upper respiratory tract infection (1.3%)
Nausea (2.9%)
Nasopharyngitis (1%)
Dizziness (2.3%)
Sources:
25 mg 1 times / day single, oral
Dose: 25 mg, 1 times / day
Route: oral
Route: single
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 18-71 years
n = 478
Health Status: unhealthy
Condition: migraine
Age Group: 18-71 years
Sex: M+F
Population Size: 478
Sources:
Other AEs: Nausea, Dizziness...
Other AEs:
Nausea (2.5%)
Dizziness (2.1%)
Sources:
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, 18-75 years
n = 485
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 485
Sources:
Disc. AE: Nausea...
Other AEs: Nausea, Somnolence...
AEs leading to
discontinuation/dose reduction:
Nausea
Other AEs:
Nausea (4%)
Somnolence (3%)
Dry mouth (2%)
Sources:
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 18-75 years
n = 488
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 488
Sources:
Other AEs: Upper respiratory tract infection, Nausea...
Other AEs:
Upper respiratory tract infection (2.7%)
Nausea (2.5%)
Nasopharyngitis (2.3%)
Dizziness (2%)
Sources:
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 18-75 years
n = 488
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 488
Sources:
Other AEs: ALT increased, AST increased...
Other AEs:
ALT increased (0.4%)
AST increased (0.2%)
ALP increased (0.2%)
Sources:
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 18-75 years
n = 954
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 954
Sources:
Other AEs: Nausea, Somnolence...
Other AEs:
Nausea (2%)
Somnolence (2%)
Dry mouth (< 1%)
Sources:
50 mg 1 times / day single, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: single
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 18-75 years
n = 488
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 488
Sources:
Other AEs: Nausea, Dizziness...
Other AEs:
Nausea (2%)
Dizziness (1.4%)
Sources:
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Disc. AE: Abnormal ECG, Extrasystoles...
Other AEs: Nasopharyngitis, Upper respiratory tract infection...
AEs leading to
discontinuation/dose reduction:
Abnormal ECG (0.2%)
Extrasystoles (0.2%)
Nausea (0.2%)
Palpitations (0.2%)
Pruritus (0.2%)
ALT increased (0.2%)
AST increased (0.2%)
Other AEs:
Nasopharyngitis (grade 1-2, 11.5%)
Upper respiratory tract infection (grade 1-2, 10.8%)
Sinusitis (grade 1-2, 6.4%)
Urinary tract infection (grade 1-2, 6.4%)
Influenza (grade 1-2, 6.1%)
Nausea (grade 1-2, 4.6%)
Bronchitis (grade 1-2, 4.4%)
Blood creatine phosphokinase increased (grade 1-2, 3.9%)
ALT increased (grade 1-2, 3.7%)
AST increased (grade 1-2, 3.4%)
Back pain (grade 1-2, 3.4%)
Nephrolithiasis (grade 1-2, 3.2%)
Dizziness (grade 1-2, 2.9%)
Anxiety (grade 1-2, 2.7%)
Cough (grade 1-2, 2.7%)
Diarrhea (grade 1-2, 2.7%)
Arthralgia (grade 1-2, 2.4%)
Gastroenteritis viral (grade 1-2, 2.4%)
Muscle strain (grade 1-2, 2.4%)
Depression (grade 1-2, 1.2%)
Migraine (grade 1-2, 1%)
Abdominal pain (grade 1-2, 0.5%)
Sources:
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Disc. AE: Nausea, Thrombocytopenia...
Other AEs: Nasopharyngitis, Upper respiratory tract infection...
AEs leading to
discontinuation/dose reduction:
Nausea (0.2%)
Thrombocytopenia (0.2%)
Urticaria (0.2%)
Vomiting (0.2%)
Other AEs:
Nasopharyngitis (grade 1-2, 8.2%)
Upper respiratory tract infection (grade 1-2, 11.6%)
Sinusitis (grade 1-2, 6.9%)
Urinary tract infection (grade 1-2, 5.4%)
Influenza (grade 1-2, 4.2%)
Nausea (grade 1-2, 4.7%)
Bronchitis (grade 1-2, 3.2%)
Blood creatine phosphokinase increased (grade 1-2, 2.5%)
ALT increased (grade 1-2, 2.2%)
AST increased (grade 1-2, 1.7%)
Back pain (grade 1-2, 3.5%)
Nephrolithiasis (grade 1-2, 1%)
Dizziness (grade 1-2, 1.2%)
Anxiety (grade 1-2, 1.5%)
Cough (grade 1-2, 2%)
Diarrhea (grade 1-2, 2.5%)
Arthralgia (grade 1-2, 2.7%)
Gastroenteritis viral (grade 1-2, 1.7%)
Muscle strain (grade 1-2, 0.5%)
Depression (grade 1-2, 3.2%)
Migraine (grade 1-2, 1.5%)
Abdominal pain (grade 1-2, 1%)
Epididymitis (grade 1-2, 3.2%)
Testicular pain (grade 1-2, 3.2%)
Sources:
400 mg 1 times / day single, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: single
Dose: 400 mg, 1 times / day
Sources:
healthy, mean age 29.2 years
n = 76
Health Status: healthy
Age Group: mean age 29.2 years
Sex: M+F
Population Size: 76
Sources:
Other AEs: Nausea, Diarrhea...
Other AEs:
Nausea (1.3%)
Diarrhea (2.6%)
Abdominal pain (1.3%)
Vomiting (1.3%)
Medical device site reaction (1.3%)
Vessel puncture site pain (2.6%)
Electrocardiogram QT prolonged (1.3%)
AST increased (1.3%)
Headache (2.6%)
Insomnia (1.3%)
Cough (1.3%)
Oropharyngeal pain (1.3%)
Sources:
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
healthy, range 21–51 years
n = 6
Health Status: healthy
Age Group: range 21–51 years
Sex: M
Population Size: 6
Sources:
Other AEs: Headache, Nausea...
Other AEs:
Headache (grade 1-2, 16.7%)
Nausea (grade 1-2, 16.7%)
Abdominal discomfort (grade 1-2, 16.7%)
Abdominal pain upper (grade 1-2, 16.7%)
Application site irritation (grade 1-2, 16.7%)
Herpes simplex (grade 1-2, 16.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Nasopharyngitis 1%
25 mg multiple, oral
Dose: 25 mg
Route: oral
Route: multiple
Dose: 25 mg
Sources:
unhealthy, 18-71 years
n = 478
Health Status: unhealthy
Condition: migraine
Age Group: 18-71 years
Sex: M+F
Population Size: 478
Sources:
Upper respiratory tract infection 1.3%
25 mg multiple, oral
Dose: 25 mg
Route: oral
Route: multiple
Dose: 25 mg
Sources:
unhealthy, 18-71 years
n = 478
Health Status: unhealthy
Condition: migraine
Age Group: 18-71 years
Sex: M+F
Population Size: 478
Sources:
Dizziness 2.3%
25 mg multiple, oral
Dose: 25 mg
Route: oral
Route: multiple
Dose: 25 mg
Sources:
unhealthy, 18-71 years
n = 478
Health Status: unhealthy
Condition: migraine
Age Group: 18-71 years
Sex: M+F
Population Size: 478
Sources:
Nausea 2.9%
25 mg multiple, oral
Dose: 25 mg
Route: oral
Route: multiple
Dose: 25 mg
Sources:
unhealthy, 18-71 years
n = 478
Health Status: unhealthy
Condition: migraine
Age Group: 18-71 years
Sex: M+F
Population Size: 478
Sources:
Dizziness 2.1%
25 mg 1 times / day single, oral
Dose: 25 mg, 1 times / day
Route: oral
Route: single
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 18-71 years
n = 478
Health Status: unhealthy
Condition: migraine
Age Group: 18-71 years
Sex: M+F
Population Size: 478
Sources:
Nausea 2.5%
25 mg 1 times / day single, oral
Dose: 25 mg, 1 times / day
Route: oral
Route: single
Dose: 25 mg, 1 times / day
Sources:
unhealthy, 18-71 years
n = 478
Health Status: unhealthy
Condition: migraine
Age Group: 18-71 years
Sex: M+F
Population Size: 478
Sources:
Dry mouth 2%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, 18-75 years
n = 485
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 485
Sources:
Somnolence 3%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, 18-75 years
n = 485
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 485
Sources:
Nausea 4%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, 18-75 years
n = 485
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 485
Sources:
Nausea Disc. AE
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, 18-75 years
n = 485
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 485
Sources:
Dizziness 2%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 18-75 years
n = 488
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 488
Sources:
Nasopharyngitis 2.3%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 18-75 years
n = 488
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 488
Sources:
Nausea 2.5%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 18-75 years
n = 488
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 488
Sources:
Upper respiratory tract infection 2.7%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 18-75 years
n = 488
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 488
Sources:
ALP increased 0.2%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 18-75 years
n = 488
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 488
Sources:
AST increased 0.2%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 18-75 years
n = 488
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 488
Sources:
ALT increased 0.4%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 18-75 years
n = 488
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 488
Sources:
Nausea 2%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 18-75 years
n = 954
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 954
Sources:
Somnolence 2%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 18-75 years
n = 954
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 954
Sources:
Dry mouth < 1%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, 18-75 years
n = 954
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 954
Sources:
Dizziness 1.4%
50 mg 1 times / day single, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: single
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 18-75 years
n = 488
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 488
Sources:
Nausea 2%
50 mg 1 times / day single, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: single
Dose: 50 mg, 1 times / day
Sources:
unhealthy, 18-75 years
n = 488
Health Status: unhealthy
Condition: migraine
Age Group: 18-75 years
Sex: M+F
Population Size: 488
Sources:
ALT increased 0.2%
Disc. AE
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
AST increased 0.2%
Disc. AE
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Abnormal ECG 0.2%
Disc. AE
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Extrasystoles 0.2%
Disc. AE
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Nausea 0.2%
Disc. AE
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Palpitations 0.2%
Disc. AE
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Pruritus 0.2%
Disc. AE
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Abdominal pain grade 1-2, 0.5%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Migraine grade 1-2, 1%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Depression grade 1-2, 1.2%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Upper respiratory tract infection grade 1-2, 10.8%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Nasopharyngitis grade 1-2, 11.5%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Arthralgia grade 1-2, 2.4%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Gastroenteritis viral grade 1-2, 2.4%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Muscle strain grade 1-2, 2.4%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Anxiety grade 1-2, 2.7%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Cough grade 1-2, 2.7%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Diarrhea grade 1-2, 2.7%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Dizziness grade 1-2, 2.9%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Nephrolithiasis grade 1-2, 3.2%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
AST increased grade 1-2, 3.4%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Back pain grade 1-2, 3.4%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
ALT increased grade 1-2, 3.7%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Blood creatine phosphokinase increased grade 1-2, 3.9%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Bronchitis grade 1-2, 4.4%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Nausea grade 1-2, 4.6%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Influenza grade 1-2, 6.1%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Sinusitis grade 1-2, 6.4%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Urinary tract infection grade 1-2, 6.4%
100 mg multiple, oral
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources:
unhealthy, average 42 years
n = 409
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 409
Sources:
Nausea 0.2%
Disc. AE
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Thrombocytopenia 0.2%
Disc. AE
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Urticaria 0.2%
Disc. AE
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Vomiting 0.2%
Disc. AE
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Muscle strain grade 1-2, 0.5%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Abdominal pain grade 1-2, 1%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Nephrolithiasis grade 1-2, 1%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Dizziness grade 1-2, 1.2%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Anxiety grade 1-2, 1.5%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Migraine grade 1-2, 1.5%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
AST increased grade 1-2, 1.7%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Gastroenteritis viral grade 1-2, 1.7%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Upper respiratory tract infection grade 1-2, 11.6%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Cough grade 1-2, 2%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
ALT increased grade 1-2, 2.2%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Blood creatine phosphokinase increased grade 1-2, 2.5%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Diarrhea grade 1-2, 2.5%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Arthralgia grade 1-2, 2.7%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Bronchitis grade 1-2, 3.2%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Depression grade 1-2, 3.2%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Epididymitis grade 1-2, 3.2%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Testicular pain grade 1-2, 3.2%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Back pain grade 1-2, 3.5%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Influenza grade 1-2, 4.2%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Nausea grade 1-2, 4.7%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Urinary tract infection grade 1-2, 5.4%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Sinusitis grade 1-2, 6.9%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
Nasopharyngitis grade 1-2, 8.2%
50 mg multiple, oral
Recommended
Dose: 50 mg
Route: oral
Route: multiple
Dose: 50 mg
Sources:
unhealthy, average 42 years
n = 404
Health Status: unhealthy
Condition: migraine
Age Group: average 42 years
Sex: M+F
Population Size: 404
Sources:
AST increased 1.3%
400 mg 1 times / day single, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: single
Dose: 400 mg, 1 times / day
Sources:
healthy, mean age 29.2 years
n = 76
Health Status: healthy
Age Group: mean age 29.2 years
Sex: M+F
Population Size: 76
Sources:
Abdominal pain 1.3%
400 mg 1 times / day single, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: single
Dose: 400 mg, 1 times / day
Sources:
healthy, mean age 29.2 years
n = 76
Health Status: healthy
Age Group: mean age 29.2 years
Sex: M+F
Population Size: 76
Sources:
Cough 1.3%
400 mg 1 times / day single, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: single
Dose: 400 mg, 1 times / day
Sources:
healthy, mean age 29.2 years
n = 76
Health Status: healthy
Age Group: mean age 29.2 years
Sex: M+F
Population Size: 76
Sources:
Electrocardiogram QT prolonged 1.3%
400 mg 1 times / day single, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: single
Dose: 400 mg, 1 times / day
Sources:
healthy, mean age 29.2 years
n = 76
Health Status: healthy
Age Group: mean age 29.2 years
Sex: M+F
Population Size: 76
Sources:
Insomnia 1.3%
400 mg 1 times / day single, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: single
Dose: 400 mg, 1 times / day
Sources:
healthy, mean age 29.2 years
n = 76
Health Status: healthy
Age Group: mean age 29.2 years
Sex: M+F
Population Size: 76
Sources:
Medical device site reaction 1.3%
400 mg 1 times / day single, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: single
Dose: 400 mg, 1 times / day
Sources:
healthy, mean age 29.2 years
n = 76
Health Status: healthy
Age Group: mean age 29.2 years
Sex: M+F
Population Size: 76
Sources:
Nausea 1.3%
400 mg 1 times / day single, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: single
Dose: 400 mg, 1 times / day
Sources:
healthy, mean age 29.2 years
n = 76
Health Status: healthy
Age Group: mean age 29.2 years
Sex: M+F
Population Size: 76
Sources:
Oropharyngeal pain 1.3%
400 mg 1 times / day single, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: single
Dose: 400 mg, 1 times / day
Sources:
healthy, mean age 29.2 years
n = 76
Health Status: healthy
Age Group: mean age 29.2 years
Sex: M+F
Population Size: 76
Sources:
Vomiting 1.3%
400 mg 1 times / day single, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: single
Dose: 400 mg, 1 times / day
Sources:
healthy, mean age 29.2 years
n = 76
Health Status: healthy
Age Group: mean age 29.2 years
Sex: M+F
Population Size: 76
Sources:
Diarrhea 2.6%
400 mg 1 times / day single, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: single
Dose: 400 mg, 1 times / day
Sources:
healthy, mean age 29.2 years
n = 76
Health Status: healthy
Age Group: mean age 29.2 years
Sex: M+F
Population Size: 76
Sources:
Headache 2.6%
400 mg 1 times / day single, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: single
Dose: 400 mg, 1 times / day
Sources:
healthy, mean age 29.2 years
n = 76
Health Status: healthy
Age Group: mean age 29.2 years
Sex: M+F
Population Size: 76
Sources:
Vessel puncture site pain 2.6%
400 mg 1 times / day single, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: single
Dose: 400 mg, 1 times / day
Sources:
healthy, mean age 29.2 years
n = 76
Health Status: healthy
Age Group: mean age 29.2 years
Sex: M+F
Population Size: 76
Sources:
Abdominal discomfort grade 1-2, 16.7%
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
healthy, range 21–51 years
n = 6
Health Status: healthy
Age Group: range 21–51 years
Sex: M
Population Size: 6
Sources:
Abdominal pain upper grade 1-2, 16.7%
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
healthy, range 21–51 years
n = 6
Health Status: healthy
Age Group: range 21–51 years
Sex: M
Population Size: 6
Sources:
Application site irritation grade 1-2, 16.7%
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
healthy, range 21–51 years
n = 6
Health Status: healthy
Age Group: range 21–51 years
Sex: M
Population Size: 6
Sources:
Headache grade 1-2, 16.7%
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
healthy, range 21–51 years
n = 6
Health Status: healthy
Age Group: range 21–51 years
Sex: M
Population Size: 6
Sources:
Herpes simplex grade 1-2, 16.7%
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
healthy, range 21–51 years
n = 6
Health Status: healthy
Age Group: range 21–51 years
Sex: M
Population Size: 6
Sources:
Nausea grade 1-2, 16.7%
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
healthy, range 21–51 years
n = 6
Health Status: healthy
Age Group: range 21–51 years
Sex: M
Population Size: 6
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
weak
weak
weak
weak
weak
weak
weak
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: Co-administration of ubrogepant with ketoconazole, a strong CYP3A4 inhibitor, resulted in a 9.7­ fold increase in ubrogepant AUC0-inf and a 5.3-fold increase in ubrogepant Cmax
Page: 7.0
no
weak
weak
weak
yes
yes
likely (co-administration study)
Comment: Drug interaction with verapamil (a combined P-gp inhibitor and moderate CYP3A4 inhibitor) resulted in a 3.5-fold increase in exposure. This increase in exposure can be due to the combined P-gp/CYP3A4 inhibition and the relative contribution of P-gp inhibition needs to be segregated to provide dose adjustment recommendation with P-gp only inhibitors
Page: 9.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.
2016 Aug
Therapeutic novelties in migraine: new drugs, new hope?
2019 Apr 17
Patents

Sample Use Guides

Migraine: ubrogepant 1 mg, 10 mg, 25 mg, 50 mg, 100 mg. Ubrogepant 100 mg was significantly superior to placebo for two-hour pain freedom but not for two-hour headache response.
Route of Administration: Oral
The binding affinity for native (Ki=0.067 nM) and cloned human (Ki=0.070 nM) and rhesus (Ki=0.079 nM) receptors was similar for ubrogepant, with relatively lower affinities for CGRP receptors of other species (ranging from Ki=9.6 to 47 nM). Ubrogepant potently blocked human α-CGRP–stimulated cAMP response (IC50 of 0.08) and exhibited highly selective antagonist activity in relation to the CGRP receptor compared with other members of the human calcitonin receptor family.
Substance Class Chemical
Created
by admin
on Sat Jun 26 14:24:18 UTC 2021
Edited
by admin
on Sat Jun 26 14:24:18 UTC 2021
Record UNII
AD0O8X2QJR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
UBROGEPANT
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
UBROGEPANT [WHO-DD]
Common Name English
SPIRO(6H-CYCLOPENTA(B)PYRIDINE-6,3'-(3H)PYRROLO(2,3-B)PYRIDINE)-3-CARBOXAMIDE, 1',2',5,7-TETRAHYDRO-N-((3S,5S,6R)-6-METHYL-2-OXO-5-PHENYL-1-(2,2,2-TRIFLUOROETHYL)-3-PIPERIDINYL)-2'-OXO-, (3'S)-
Systematic Name English
UBROGEPANT ANHYDROUS
Common Name English
UBRELVY
Brand Name English
(3'S)-N-((3S,5S,6R)-6-METHYL-2-OXO-5-PHENYL-1-(2,2,2-TRIFLUOROETHYL)PIPERIDIN-3-YL)-2'-OXO-1',2',5,7-TETRAHYDROSPIRO(CYCLOPENTA(B)PYRIDINE-6,3'-PYRROLO(2,3-B)PYRIDINE)-3-CARBOXAMIDE
Systematic Name English
UBROGEPANT [USAN]
Common Name English
UBROGEPANT [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C241
Created by admin on Sat Jun 26 14:24:19 UTC 2021 , Edited by admin on Sat Jun 26 14:24:19 UTC 2021
Code System Code Type Description
DRUG CENTRAL
5361
Created by admin on Sat Jun 26 14:24:19 UTC 2021 , Edited by admin on Sat Jun 26 14:24:19 UTC 2021
PRIMARY
DRUG BANK
DB15328
Created by admin on Sat Jun 26 14:24:19 UTC 2021 , Edited by admin on Sat Jun 26 14:24:19 UTC 2021
PRIMARY
ChEMBL
CHEMBL2364638
Created by admin on Sat Jun 26 14:24:19 UTC 2021 , Edited by admin on Sat Jun 26 14:24:19 UTC 2021
PRIMARY
FDA UNII
AD0O8X2QJR
Created by admin on Sat Jun 26 14:24:19 UTC 2021 , Edited by admin on Sat Jun 26 14:24:19 UTC 2021
PRIMARY
INN
9803
Created by admin on Sat Jun 26 14:24:19 UTC 2021 , Edited by admin on Sat Jun 26 14:24:19 UTC 2021
PRIMARY
EPA CompTox
1374248-77-7
Created by admin on Sat Jun 26 14:24:19 UTC 2021 , Edited by admin on Sat Jun 26 14:24:19 UTC 2021
PRIMARY
PUBCHEM
68748835
Created by admin on Sat Jun 26 14:24:19 UTC 2021 , Edited by admin on Sat Jun 26 14:24:19 UTC 2021
PRIMARY
RXCUI
2268216
Created by admin on Sat Jun 26 14:24:19 UTC 2021 , Edited by admin on Sat Jun 26 14:24:19 UTC 2021
PRIMARY
CAS
1374248-77-7
Created by admin on Sat Jun 26 14:24:19 UTC 2021 , Edited by admin on Sat Jun 26 14:24:19 UTC 2021
PRIMARY
NCI_THESAURUS
C152790
Created by admin on Sat Jun 26 14:24:19 UTC 2021 , Edited by admin on Sat Jun 26 14:24:19 UTC 2021
PRIMARY
LACTMED
Ubrogepant
Created by admin on Sat Jun 26 14:24:19 UTC 2021 , Edited by admin on Sat Jun 26 14:24:19 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
MAJOR
EXCRETED UNCHANGED
Based on results from Study MK-1602 P009, following single oral dose administration of radio-labelled [14C]-ubrogepant to healthy male subjects, approximately 42% and 6% of the dose was recovered as unchanged ubrogepant in feces and urine, respectively.
URINE
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
EXCRETED UNCHANGED
Based on results from Study MK-1602 P009, following single oral dose administration of radio-labelled [14C]-ubrogepant to healthy male subjects, approximately 42% and 6% of the dose was recovered as unchanged ubrogepant in feces and urine, respectively.
FECAL
TARGET -> INHIBITOR
TRANSPORTER -> SUBSTRATE
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Volume of Distribution PHARMACOKINETIC